Clinical trials: Olanzapine
- Drug or intervention Olanzapine
- Funder type Industry (pharma, biotech, devices)
- Accepts healthy volunteers yes
Healthy
Fasting Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
The objective of this study was to investigate the bioequivalence of Mylan's olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fasting conditions.
- Trial name
- NCT00648921
- Testing
- Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg
- Where
- United States
- Volunteers
- 30 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Fed
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fed Condition
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fed conditions and to monitor adverse events and ensure safety of subjects.
- Trial name
- NCT01503450
- Testing
- Olanzapine OD Tablets 5 mg
- Where
- India
- Volunteers
- 26 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Healthy
Evaluation of Safety, Drug-Drug Interactions and Pharmacokinetic Profiles of Co-Administration of Betahistine With Olanzapine in Healthy Female Subjects
This will be a phase I, randomized, two-arm, double-blind, placebo-controlled, sequential study in up to 50 healthy female subjects.
- Trial name
- NCT00852956
- Testing
- Betahistine
- Where
- 2 sites in Romania
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- OBEcure Ltd.
Fed
Bioequivalence Study of Olanzapine Tablets, 5 mg Under Fed Study
The purpose of this study is to compare the bioequivalence and characterize the profile of the olanzapine tablets, 5 mg with zyprexa tablets, 5 mg in healthy, adult, human subjects under fed conditions and to monitor the adverse…
- Trial name
- NCT01503424
- Testing
- Olanzapine
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Healthy
A Study to Compare Capillary and Venous Whole Blood and Plasma Concentrations of Five Antipsychotics
The purpose of this study is to compare capillary (the smallest of a body's blood vessels) and venous whole blood and plasma concentrations of 5 antipsychotics after given of a single oral, immediate-release dose to healthy…
- Trial name
- NCT01607762
- Testing
- Aripiprazole, Quetiapine, Olanzapine
- Where
- Belgium
- Volunteers
- 31 people, healthy volunteers welcome
- Sponsor
- Janssen Research & Development, LLC
Weight-Gain Prevention
A Two-Week Study of the Efficacy and Safety of Mifepristone in the Prevention of Olanzapine-Induced Weight Gain
This is a two-week study testing the efficacy and safety of mifepristone in the prevention of olanzapine-induced weight gain in healthy male volunteers by measuring changes in body weight and BMI.
- Trial name
- NCT00455442
- Testing
- Mifepristone
- Where
- India
- Volunteers
- 57 people, healthy volunteers welcome
- Sponsor
- Corcept Therapeutics
Drug-induced Weight Gain
Effect of RDX-002 on Postprandial Triglycerides in Subjects Treated With Olanzapine
This Phase 1b Study RDX-002-22-09 has been planned to evaluate the effect of RDX-002 on postprandial triglycerides and ApoB48 levels in normal healthy subjects treated with the atypical antipsychotic drug, olanzapine.
- Trial name
- NCT05857566
- Testing
- RDX-002 + Olanzipine, Olanzapine
- Where
- United States
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Response Pharmaceuticals
Healthy Volunteers
An Insulin Sensitivity Study in Healthy Subjects
This study will characterize insulin sensitivity in response to treatment with ALKS 3831, olanzapine, and placebo.
- Trial name
- NCT02922426
- Testing
- ALKS 3831, Olanzapine
- Where
- United States
- Volunteers
- 60 people, healthy volunteers welcome
- Sponsor
- Alkermes, Inc.
Fasting
Bioequivalence Study of Olanzapine Tablets, 5 mg of Dr. Reddy's Under Fasting Conditions
The purpose of this study is to compare the bioequivalence and characterize the profile of the olanzapine tablets, 5 mg with zyprexa tablets, 5 mg in healthy, adult, human subjects under fasting conditions and to monitor the…
- Trial name
- NCT01503398
- Testing
- Olanzapine
- Where
- India
- Volunteers
- 48 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Fasting
Bioequivalence Study of Olanzapine Orally Disintegrating Tablets, 5 mg Under Fasting Condition
The purpose of this study is to compare the single oral dose bioequivalence of olanzapine 5 mg OD tablets with Zyprexa Zydis 5 mg tablets under fasting conditions and to monitor adverse events and ensure safety of subjects.
- Trial name
- NCT01503437
- Testing
- Olanzapine OD Tablets 5 mg
- Where
- India
- Volunteers
- 22 people, healthy volunteers welcome
- Sponsor
- Dr. Reddy's Laboratories Limited
Healthy
Fasting Study of Olanzapine Tablets 20 mg and Zyprexa® Tablets 20 mg
The objective of this study was to investigate the bioequivalence of Mylan olanzapine 20 mg tablets to Eli Lilly Zyprexa® 20 mg tablets following a single, oral 20 mg (1 x 20 mg) dose administration under fasting conditions.
- Trial name
- NCT00647972
- Testing
- Olanzapine Tablets 20 mg, Zyprexa® Tablets 20 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Schizophrenia
Olanzapine Versus An Active Comparator in the Treatment of Schizophrenia
The purpose of this study is to determine how Olanzapine compares to an active comparator in the treatment of schizophrenia
- Trial name
- NCT00036088
- Testing
- Olanzapine
- Where
- 60 sites in United States, Argentina and 10 more
- Volunteers
- 530 people, healthy volunteers welcome
- Sponsor
- Eli Lilly and Company
Healthy
Bioequivalence Study of Torrent Pharmaceutical Ltd.'s Olanzapine Orally Disintegrating 5mg Tablets Under Fasting Condition
Objective: Primary objective of the present study was to compare the single dose bioavailability of Torrent's Olanzapine Orally Disintegrating 5 mg Tablets versus Zyprexa® Zydis® 5 mg Tablets (Reference formulation; Eli Lilly and…
- Trial name
- NCT01996488
- Testing
- Olanzapine Orally Disintegrating Tablets 5mg
- Where
- India
- Volunteers
- healthy volunteers welcome
- Sponsor
- Torrent Pharmaceuticals Limited
Schizophrenia, Psychotic Disorders
A Study to Compare Disease Progression and Modification Following Treatment With Paliperidone Palmitate Long-Acting Injection or Oral Antipsychotics in Participant's With Recent-onset Schizophrenia or Schizophreniform
The purpose of the study is to compare effectiveness of paliperidone palmitate (PP: paliperidone palmitate once-monthly and 3-month injections) versus oral antipsychotic (OAP [that is oral paliperidone extended release {ER}, oral…
- Trial name
- DREaM (NCT02431702)
- Testing
- Aripiprazole, Haloperidol, Olanzapine
- Where
- 38 sites in United States, Brazil and 1 more
- Volunteers
- 337 people, healthy volunteers welcome
- Sponsor
- Janssen Scientific Affairs, LLC
Chemotherapy Induced Nausea and Vomiting
Prevention of Breakthrough CINV in Patients Receiving Moderately or Highly Emetogenic Chemotherapy
The purpose of the proposed study is to provide a clinical approach to chemotherapy induced nausea and vomiting (CINV) prophylaxis in cycle 2 of moderately emetogenic chemotherapy or highly emetogenic chemotherapy for patients…
- Trial name
- NCT06065722
- Testing
- Akynzeo
- Where
- United States
- Volunteers
- 100 people, healthy volunteers welcome
- Sponsor
- Simon Williamson Clinic
Healthy
A Study of Olanzapine After Intranasal and Intramuscular Administration
NRL-4, a nasal spray formulation of the atypical antipsychotic olanzapine is being developed by Neurelis Inc. for use as a rescue medication for acute episodes of agitation in schizophrenia, schizoaffective and bipolar I…
- Trial name
- NCT06600477
- Testing
- olanzapine
- Where
- Jordan
- Volunteers
- 24 people, healthy volunteers welcome
- Sponsor
- Neurelis, Inc.
Schizophrenia
A First In Human Study Of PF-00184562 In Healthy Volunteers
The purposes of this study are: To determine the safety, tolerability and pharmacokinetics of single doses of PF-00184562; and To explore the exposure-response relationship of neuropsychometric and tolerability measures of…
- Trial name
- NCT00150215
- Testing
- PF-00184562, Olanzapine
- Where
- United States
- Volunteers
- 18 people, healthy volunteers welcome
- Sponsor
- Pfizer
Healthy
Food Study of Olanzapine Tablets 5 mg and Zyprexa® Tablets 5 mg
The objective of this study was to investigate the bioequivalence of Mylan olanzapine 5 mg tablets to Eli Lilly's Zyprexa® 5 mg tablets following a single, oral 5 mg (1 x 5 mg) dose administered under fed conditions.
- Trial name
- NCT00647777
- Testing
- Olanzapine Tablets 5 mg, Zyprexa® Tablets 5 mg
- Where
- United States
- Volunteers
- 32 people, healthy volunteers welcome
- Sponsor
- Mylan Pharmaceuticals Inc
Healthy
Evaluation of Co-Administration of Betahistine as Adjunctive to Olanzapine in Healthy Subjects
The study aims to evaluate the safety and pharmacokinetics of extended release and standard formulations of betahistine when administered as monotherapy and as compared to their safety and pharmacokinetics when co-administered…
- Trial name
- NCT01168336
- Testing
- Betahistine standard formulation, Betahistine Extended Release formulation
- Where
- 2 sites in Romania
- Volunteers
- 90 people, healthy volunteers welcome
- Sponsor
- OBEcure Ltd.
Acute Agitation
Safety and Tolerability of INP105 (Olanzapine by I231 POD® Device) Nasal Spray in Healthy Volunteers - SNAP 101
The purpose of this study is to evaluate the safety, pharmacokinetics (PK), and pharmacodynamics (PD) of INP105, which is an investigational drug-device combination product comprised of the drug component OLZ administered by a…
- Trial name
- SNAP101 (NCT03624322)
- Testing
- Zyprexa IM, Zydis, INP105
- Where
- Australia
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Impel Pharmaceuticals